8-K: Terns Pharmaceuticals Reports Positive Phase 1 Data and Secures Funding, Extending Cash Runway to 2028

Terns Pharmaceuticals announced positive Phase 1 results for its obesity drug TERN-601, plans for a Phase 2 trial, and a successful equity raise extending its cash runway into 2028.

Summary

• Terns Pharmaceuticals reported its third quarter 2024 financial results and provided corporate updates.
• The company highlighted positive topline results from its Phase 1 study of TERN-601, an oral GLP-1R agonist for obesity, showing significant weight loss.
• Terns plans to initiate a Phase 2 clinical trial for TERN-601 in early second quarter of 2025, with initial 12-week data expected in the second half of 2025.
• Interim data from the Phase 1 CARDINAL trial of TERN-701 for chronic myeloid leukemia (CML) is expected in early December 2024.
• The company completed an equity raise of $172.7 million in September, bringing total cash, cash equivalents, and marketable securities to $372.8 million as of September 30, 2024.
• This funding is expected to support operations into 2028.
• Research and development expenses were $15.2 million for the quarter ended September 30, 2024, compared to $14.8 million for the same period in 2023.
• General and administrative expenses were $9.8 million for the quarter ended September 30, 2024, compared to $18.4 million for the same period in 2023.
• The net loss for the quarter was $21.9 million, compared to $29.8 million for the same quarter in 2023.

Sentiment

Score: 8

Explanation: The document presents a very positive outlook with strong clinical results, a successful capital raise, and an extended cash runway. The company is making good progress on its pipeline and has a clear path forward.

Positives

• The Phase 1 results for TERN-601 are very promising, showing significant weight loss and good tolerability.
• The successful equity raise significantly strengthens the company's financial position.
• The extended cash runway into 2028 provides financial stability for ongoing and future clinical trials.
• The company is advancing multiple clinical programs across oncology and obesity.
• The reduction in general and administrative expenses year-over-year is a positive sign of cost management.

Negatives

• The company reported a net loss of $21.9 million for the quarter, although this is an improvement compared to the previous year.
• Research and development expenses remain significant, reflecting the high cost of clinical trials.

Risks

• Clinical trials are subject to inherent risks, including the possibility of unexpected safety issues or lack of efficacy.
• The company's success depends on the successful development and commercialization of its drug candidates.
• Regulatory approvals are not guaranteed and can be subject to delays.
• The company faces competition from other pharmaceutical companies developing similar treatments.
• The company's financial performance is dependent on its ability to raise additional capital in the future if required.

Future Outlook

Terns expects its current cash resources to be sufficient to fund operations into 2028. The company plans to advance its clinical programs, including initiating a Phase 2 trial for TERN-601 in early 2025 and reporting interim data for TERN-701 in early December 2024.

Management Comments

• Amy Burroughs, chief executive officer of Terns, stated that the Phase 1 study of TERN-601 demonstrated class-leading potential.
• The CEO also mentioned that the successful equity raise underscores strong support for the company's pipeline and extends the cash runway into 2028.

Industry Context

The announcement is relevant to the broader pharmaceutical industry, particularly in the areas of obesity and oncology. The positive results for TERN-601 position Terns as a potential competitor in the rapidly growing market for GLP-1 receptor agonists. The development of TERN-701 also places Terns in the competitive landscape of CML treatments.

Comparison to Industry Standards

• The 5.5% mean weight loss observed with TERN-601 in 28 days is competitive with other oral GLP-1 agonists in early-stage trials, such as those from companies like Pfizer and Eli Lilly, although direct comparisons are difficult due to differences in trial design and patient populations.
• The company's cash runway into 2028 is a significant advantage compared to many other clinical-stage biotechs, which often require frequent capital raises.
• The planned Phase 2 trial for TERN-601 is a critical next step, and its success will be compared to the progress of other companies in the obesity space, such as Novo Nordisk and Amgen.
• The development of TERN-701 as an allosteric BCR-ABL inhibitor is also notable, as it targets a specific mechanism of action in CML, similar to other targeted therapies from companies like Novartis and Bristol Myers Squibb.

Management Changes

Stakeholder Impact

• Shareholders will benefit from the increased cash position and the potential for future growth.
• Employees will have job security due to the extended cash runway.
• Patients may benefit from the development of new treatments for obesity and CML.
• The company's suppliers and partners will benefit from the continued operations and growth of the company.

Next Steps

• Terns plans to share interim data from the Phase 1 CARDINAL trial of TERN-701 in early December 2024.
• The company plans to initiate a Phase 2 clinical trial for TERN-601 in early second quarter of 2025.
• Terns will continue to evaluate opportunities for TERN-501 in metabolic diseases.
• The company is prioritizing its discovery efforts on nominating a GIPR antagonist development candidate.

Key Dates

Keywords

TERN-601, TERN-701, obesity, chronic myeloid leukemia, GLP-1R agonist, BCR-ABL inhibitor, clinical trial, pharmaceutical, biotechnology, equity raise, weight loss, oncology